zepzelca
zepzelca: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Jazz Pharmaceuticals plc (JAZZ) | Approved |
FDA Decisions
Frequently asked questions
Who is developing zepzelca?
zepzelca is being developed by Jazz Pharmaceuticals plc.
What is zepzelca's latest FDA decision?
The most recent tracked FDA decision for zepzelca is Approval for 1 INDICATIONS AND USAGE ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. ( 1.1 ) • For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progressi, dated June 15, 2020.
Get deeper analysis on zepzelca
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis